Cargando…

Molecular Mechanisms of Hypertensive Nephropathy: Renoprotective Effect of Losartan through Hsp70

Hypertensive nephrosclerosis is the second most common cause of end-stage renal disease after diabetes. For years, hypertensive kidney disease has been focused on the afferent arterioles and glomeruli damage and the involvement of the renin angiotensin system (RAS). Nonetheless, in recent years, nov...

Descripción completa

Detalles Bibliográficos
Autores principales: Costantino, Valeria Victoria, Gil Lorenzo, Andrea Fernanda, Bocanegra, Victoria, Vallés, Patricia G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619557/
https://www.ncbi.nlm.nih.gov/pubmed/34831368
http://dx.doi.org/10.3390/cells10113146
_version_ 1784605021656055808
author Costantino, Valeria Victoria
Gil Lorenzo, Andrea Fernanda
Bocanegra, Victoria
Vallés, Patricia G.
author_facet Costantino, Valeria Victoria
Gil Lorenzo, Andrea Fernanda
Bocanegra, Victoria
Vallés, Patricia G.
author_sort Costantino, Valeria Victoria
collection PubMed
description Hypertensive nephrosclerosis is the second most common cause of end-stage renal disease after diabetes. For years, hypertensive kidney disease has been focused on the afferent arterioles and glomeruli damage and the involvement of the renin angiotensin system (RAS). Nonetheless, in recent years, novel evidence has demonstrated that persistent high blood pressure injures tubular cells, leading to epithelial–mesenchymal transition (EMT) and tubulointerstitial fibrosis. Injury primarily determined at the glomerular level by hypertension causes changes in post-glomerular peritubular capillaries that in turn induce endothelial damage and hypoxia. Microvasculature dysfunction, by inducing hypoxic environment, triggers inflammation, EMT with epithelial cells dedifferentiation and fibrosis. Hypertensive kidney disease also includes podocyte effacement and loss, leading to disruption of the filtration barrier. This review highlights the molecular mechanisms and histologic aspects involved in the pathophysiology of hypertensive kidney disease incorporating knowledge about EMT and tubulointerstitial fibrosis. The role of the Hsp70 chaperone on the angiotensin II–induced EMT after angiotensin II type 1 receptor (AT(1)R) blockage, as a possible molecular target for therapeutic strategy against hypertensive renal damage is discussed.
format Online
Article
Text
id pubmed-8619557
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86195572021-11-27 Molecular Mechanisms of Hypertensive Nephropathy: Renoprotective Effect of Losartan through Hsp70 Costantino, Valeria Victoria Gil Lorenzo, Andrea Fernanda Bocanegra, Victoria Vallés, Patricia G. Cells Review Hypertensive nephrosclerosis is the second most common cause of end-stage renal disease after diabetes. For years, hypertensive kidney disease has been focused on the afferent arterioles and glomeruli damage and the involvement of the renin angiotensin system (RAS). Nonetheless, in recent years, novel evidence has demonstrated that persistent high blood pressure injures tubular cells, leading to epithelial–mesenchymal transition (EMT) and tubulointerstitial fibrosis. Injury primarily determined at the glomerular level by hypertension causes changes in post-glomerular peritubular capillaries that in turn induce endothelial damage and hypoxia. Microvasculature dysfunction, by inducing hypoxic environment, triggers inflammation, EMT with epithelial cells dedifferentiation and fibrosis. Hypertensive kidney disease also includes podocyte effacement and loss, leading to disruption of the filtration barrier. This review highlights the molecular mechanisms and histologic aspects involved in the pathophysiology of hypertensive kidney disease incorporating knowledge about EMT and tubulointerstitial fibrosis. The role of the Hsp70 chaperone on the angiotensin II–induced EMT after angiotensin II type 1 receptor (AT(1)R) blockage, as a possible molecular target for therapeutic strategy against hypertensive renal damage is discussed. MDPI 2021-11-12 /pmc/articles/PMC8619557/ /pubmed/34831368 http://dx.doi.org/10.3390/cells10113146 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Costantino, Valeria Victoria
Gil Lorenzo, Andrea Fernanda
Bocanegra, Victoria
Vallés, Patricia G.
Molecular Mechanisms of Hypertensive Nephropathy: Renoprotective Effect of Losartan through Hsp70
title Molecular Mechanisms of Hypertensive Nephropathy: Renoprotective Effect of Losartan through Hsp70
title_full Molecular Mechanisms of Hypertensive Nephropathy: Renoprotective Effect of Losartan through Hsp70
title_fullStr Molecular Mechanisms of Hypertensive Nephropathy: Renoprotective Effect of Losartan through Hsp70
title_full_unstemmed Molecular Mechanisms of Hypertensive Nephropathy: Renoprotective Effect of Losartan through Hsp70
title_short Molecular Mechanisms of Hypertensive Nephropathy: Renoprotective Effect of Losartan through Hsp70
title_sort molecular mechanisms of hypertensive nephropathy: renoprotective effect of losartan through hsp70
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619557/
https://www.ncbi.nlm.nih.gov/pubmed/34831368
http://dx.doi.org/10.3390/cells10113146
work_keys_str_mv AT costantinovaleriavictoria molecularmechanismsofhypertensivenephropathyrenoprotectiveeffectoflosartanthroughhsp70
AT gillorenzoandreafernanda molecularmechanismsofhypertensivenephropathyrenoprotectiveeffectoflosartanthroughhsp70
AT bocanegravictoria molecularmechanismsofhypertensivenephropathyrenoprotectiveeffectoflosartanthroughhsp70
AT vallespatriciag molecularmechanismsofhypertensivenephropathyrenoprotectiveeffectoflosartanthroughhsp70